Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
Phase II Trial Evaluating Addition of Fulvestrant to Erlotinib in Patients With Stage IIIB/IV NSCLC Who Are Stable on Erlotinib and Exhibit Positivity for Estrogen or Progesterone Receptor
Sponsor: AstraZeneca
Terminated
Study was terminated due to slow subject accrual
Other terminated trials from AstraZeneca
Other Non Small Cell Lung Carcinoma trials with similar outcome
Listed as NCT00592007, this PHASE2 trial focuses on Non Small Cell Lung Carcinoma and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jul 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Lyudmila Bazhenova, M.D.
For direct contact, visit the study record on ClinicalTrials.gov .